These experiments have uncovered a therapeutically relevant dependency on YAP/TAZ-TEAD activity in GBM, demonstrated that these tumors display a clinically relevant therapeutic vulnerability to pharmacologic treatment with VP [85]. The gene discussed is WWTR1; the disease is glioblastoma.